| Mark W. Noel |
Mark W. Noel currently works at Curis, Inc., as VP-Technology Management & Intellectual Property. Mr. Noel also formerly worked at National Cancer Institute, as Deputy Director from 1993 to 1998, Gist-Brocades NV, as Director-Regulatory Affairs Department, and Gene Logic, Inc., as Vice President-Customer Relations in 2001. Mr. Noel received his undergraduate degree from the University of Maryland. |
| Jonathan B. Zung |
Jonathan B. Zung currently works at Curis, Inc., as Chief Development Officer from 2023. Dr. Zung also formerly worked at Clinical Data Interchange Standards Consortium, Inc., as Chairman from 2015 to 2021, Labcorp Drug Development, Inc., as Group President-Clinical Development from 2016 to 2018, UCB SA, as VP & Head-Global Clinical Sciences & Operations from 2014 to 2016, WIRB- Copernicus Group, Inc., as President-Sponsor & CRO Programs from 2018 to 2020, Evelo Biosciences, Inc., as Chief Development Officer from 2021 to 2023, and Clintrax Global, Inc., as President. Dr. Zung received his doctorate degree from Emory University and undergraduate degree from Florida Institute of Technology, Inc. |
| Frank Waligora |
Frank Waligora currently works at Curis, Inc., as Vice President-Technical Operations from 2022. Mr. Waligora also formerly worked at Imara, Inc., as Vice President-Technical Operations. Mr. Waligora received his Masters Business Admin degree from Northeastern University and undergraduate degree from Rochester Institute of Technology. |
| Kimberly Steinmann |
Kimberly Steinmann is currently the Vice President-Clinical Development at Curis, Inc. Her former job was as the Executive Director-Medical at Grifols, Inc. She received her undergraduate and doctorate degrees from St. Louis University. |
| Robert E. Martell |
Robert E. Martell was the founder of Epi-Cure Pharmaceuticals, Inc. (2016) and served as President, Secretary, Treasurer & Director from 2016 to 2018. Current jobs include Independent Director at Indaptus Therapeutics, Inc. (2023), Chief Scientific Officer at Curis, Inc. (2011), Member of American Society of Clinical Oncology, Inc., Member of American Association for Cancer Research, and Professor at Tufts University School of Medicine. Former jobs include Director-Oncology Global Clinical Research at Bristol Myers Squibb Co. (2002-2005), Deputy Director-Pharmaceutical Division at Bayer Corp. (2000-2002), Deputy Director-Medical Science Unit at Bayer Pharmaceuticals Corp., Director-Neely Center at Clinical Cancer Research, Chief Medical Officer at Tesaro, Inc. (2012-2015), Chief Medical Officer & Vice President at Mirati Therapeutics, Inc. (2005-2009), Associate Chief-Hematology & Oncology Division at Tufts Medical Center, Inc., Associate Professor at Tufts Medical Center, Inc. (2009-2012), and Assistant Clinical Professor at Yale School of Medicine (2001-2005). Education includes a doctorate from Wayne State University (Michigan), an undergraduate degree from Kalamazoo College, and a doctorate from the University of Michigan. |
| Ahmed M. Hamdy |
Ahmed M. Hamdy was the founder of Vincerx Pharma, Inc. (2018), holding the title of Chairman & Chief Executive Officer from 2021 to 2024. Dr. Hamdy is also the founder of Acerta Pharma BV,Acerta Pharma LLC. Dr. Hamdy is currently an Independent Director at Andes Biotechnologies SA since 2016, a Director & Clinical Advisor at Andes Biotechnologies Global, Inc. since 2016, a Member-Presidents Council at The Palo Alto Medical Foundation since 2016, a Member-Deans Council at Baskin School of Engineering since 2019, and the Chief Medical Officer at Curis, Inc. starting in 2025. Former positions include Medical Director at ALZA Corp. from 2004 to 2006, Medical Director at Johnson & Johnson from 2004 to 2006, Senior Principal Scientist at Actavis, Inc. from 2000 to 2004, Chief Medical Officer at Pharmacyclics LLC from 2008 to 2011, and Head-Early Clinical Development at AstraZeneca PLC from 2016 to 2019. Education includes a doctorate from the University of Cairo and an undergraduate degree from KasrAlAiny School of Medicine. |
| Martyn D. Greenacre |
Martyn D. Greenacre currently works at Curis, Inc., as Chairman from 2017, Life Mist Technologies, Inc., as Chairman from 2002, and Formula Pharmaceuticals, Inc., as Director. Mr. Greenacre also formerly worked at Zynaxis, Inc., as President & Chief Executive Officer in 1997, Delsys Pharmaceutical Corp., as Chief Executive Officer & Director in 2001, Life Mist LLC, as Chairman from 2001 to 2016, Beijing Med-Pharm Corp., as Chairman in 2008, Smithkline Beecham Pharmaceuticals (India) Ltd., as Director & Chairman-European Operations from 1989 to 1992, BMP Sunstone Corp., as Chairman, Cephalon, Inc., as Director from 1992 to 2011, Creative Biomolecules, Inc., as Director from 1993 to 2000, Orchestra Therapeutics, Inc., as Director in 2008, Acusphere, Inc., as Director from 2001 to 2013, NeoStem, Inc., as Director, Caladrius Biosciences, Inc., as Director in 2011, Applera Corp., as Member-Executive Committee, and Arsenal Capital Management LP, as Senior Advisor. Mr. Greenacre received his Masters Business Admin degree from Harvard Business School and undergraduate degree from Harvard College. |
| James E. Dentzer |
James E. Dentzer currently works at Curis, Inc., as President, Chief Executive Officer & Director from 2019 and Imunon, Inc., as Independent Director from 2022. Mr. Dentzer also formerly worked at EIDP, Inc., as Chief Financial Officer-DuPont Flooring Systems, Biogen, Inc., as Controller from 2003 to 2006, Amicus Therapeutics, Inc., as Chief Financial Officer from 2006 to 2009, Dicerna Pharmaceuticals, Inc., as Chief Financial Officer from 2013 to 2015, and Valeritas, Inc., as Chief Financial Officer from 2010 to 2013. Mr. Dentzer received his undergraduate degree from Boston College and Masters Business Admin degree from The University of Chicago Booth School of Business. |
| Marc Rubin |
Marc Rubin currently works at Curis, Inc., as Independent Director from 2010, Galectin Therapeutics, Inc., as Independent Director from 2018, Soricimed Biopharma, Inc., as Director from 2018, and The Rogosin Institute, Inc., as Director. Dr. Rubin also formerly worked at Titan Pharmaceuticals, Inc., as President & Chief Executive Officer from 2007 to 2009, Schering Berlin, Inc., as Chairman, Medarex, Inc., as Director from 2007 to 2009, Titan Pharmaceuticals, Inc., as Director from 2022 to 2023, Surface Logix LLC, as Director from 2005 to 2011, Xequel Bio, Inc., as Director, Gemmus Pharma, Inc., as Independent Director from 2012 to 2014, Bayer Schering Pharma AG, as Head-Global Research & Development from 2006 to 2007, GSK Plc, as Senior Vice President-Global Clinical Pharmacology from 1990 to 2003, North Shore Medical Center, Inc., as Trustee, Bayer Pharma AG, as Head-Global Research & Development in 2007, Berlex Pharmaceuticals, Inc., as President, and Bayer HealthCare, as Member-Executive Committee. Dr. Rubin received his doctorate degree in 1980 from Weill Cornell Medical College. |
| John A. Hohneker |
John A. Hohneker currently works at Artios Pharma Ltd., as Director from 2024, Curis, Inc., as Independent Director from 2021, Trishula Therapeutics, Inc., as Director from 2020, Sonata Therapeutics, Inc., as Director, Carisma Therapeutics, Inc., as Independent Director from 2024, and Arrivent BioPharma, Inc., as Independent Director from 2024. Dr. Hohneker also formerly worked at Anokion SA, as President, Chief Executive Officer & Director, Kanyos Bio, Inc., as President, Chief Executive Officer & Director, Humanigen, Inc., as Independent Director from 2021 to 2023, Dimension Therapeutics, Inc., as Director in 2017, Evelo Biosciences, Inc., as Independent Director from 2021 to 2023, Cygnal Therapeutics, Inc., as Director, Aravive, Inc., as Independent Director from 2021 to 2024, BioTheryX, Inc., as Director, Torque Therapeutics, Inc., as Director, Forma Therapeutics, Inc., as Head-Research & Development from 2015 to 2018, and Novartis AG, as SVP & Global Head-Development & Immunology from 2001 to 2015. Dr. Hohneker received his doctorate degree from the University of Medicine & Dentistry of New Jersey, undergraduate degree from Gettysburg College, and doctorate degree from Robert Wood Johnson Medical School. |
| Anne E Borgman |
Anne E Borgman currently works at NextCure, Inc., as Independent Director from 2021, NiKang Therapeutics, Inc., as Director from 2023, Curis, Inc., as Independent Director from 2022, and Sutro Biopharma, Inc., as Chief Medical Officer from 2023. Dr. Borgman also formerly worked at Abbott Laboratories, as Head-Global Development in 2007, Exelixis, Inc., as Vice President-Clinical Research & Development from 2012 to 2019, Humanigen, Inc., as Chief Medical Officer & Vice President, Talon Therapeutics, Inc., as Chief Medical Officer & Vice President, The University of Chicago, as Clinical Associate-Pediatrics from 2001 to 2010, Jazz Pharmaceuticals Plc, as Vice President & Head-Global Therapeutic Area from 2019 to 2022, Stanford University School of Medicine, as Associate Professor from 2012 to 2022, and Kalobios Pharmaceuticals, Inc., as Associate Chief Medical Officer from 2011 to 2012. Dr. Borgman received her undergraduate degree from the University of Illinois and doctorate degree from Stritch School of Medicine. |
| Kenneth I. Kaitin |
Kenneth I. Kaitin currently works at Curis, Inc., as Independent Director from 2003, Bio-Tree Systems, Inc., as Director, Centerphase Solutions, Inc., as Director, and QCDx LLC, as Director. Dr. Kaitin also formerly worked at Phase Forward, Inc., as Director from 2007 to 2010, New England Healthcare Institute, as Director, Erevnos Corp., as Director, Tufts Center for the Study of Drug Development, as Director-Drug Development Study, Drug Information Association, as President from 1997 to 1998, and Tufts University School of Medicine, as Research Professor from 2008 to 2014. Dr. Kaitin received his graduate degree and doctorate degree from Rochester Christian University and undergraduate degree from Cornell University. |
